Ping Yang M.D., Ph.D., of the Mayo Clinic, Rochester, Minn., and colleagues conducted a study to examine the trends in the proportion of
patients with lung cancer meeting the USPSTF screening criteria.
The researchers found there was a decline in the relative proportion of
patients with lung cancer meeting the USPSTF criteria overall, from 57 percent in 1984 - 1990 to 43 percent in 2005 - 2011.
An analysis of lung cancer incidence and screening found a decline in the proportion of
patients with lung cancer meeting high - risk screening criteria, suggesting that an increasing number of patients with lung cancer would not have been candidates for screening, according to a study in the February 24 issue of JAMA.
Not exact matches
Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual
Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell
lung cancer (NSCLC),
with 58 of 78 ALK +
patients responding to treatment, including 50 of 70
patients who had progressed after previous treatment
with crizotinib, the first licensed ALK inhibitor.
Combining radiation therapy
with chemotherapy for
patients with limited metastatic non-small cell
lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC
patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual
Meeting of the American Society for Radiation Oncology (ASTRO).